You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

21 Results
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Adjuvant, Palliative
Sep 2022
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
    procarbazine
ODB - General Benefit
    lomustine
Jan 2023
Regimen
Cancer Type:
Endocrine, 
Adrenal
Intent: Adjuvant
Funding:
ODB - General Benefit
    mitotane
Nov 2021
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Adjuvant, Curative
Jan 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant, Curative, Palliative
Aug 2021
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative
Funding:
ODB - General Benefit
    megestrol - oral tablets
May 2019
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative
Funding:
ODB - General Benefit
  • medroxyprogesterone
Oct 2017
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab (Adult and Pediatric) - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Completely Resectable Stage III or IV Melanoma
Oct 2024

Pages